Dermata Therapeutics Provides Corporate Update and Reports Full Year 2022 Financial Results

February 21, 2023 4:05 PM

- End of Phase 2 meeting with FDA for DMT310 for moderate-to-severe acne expected in 2Q 2023 -- Initiation of DMT310 Phase 3 clinical trial program in moderate-to-severe acne patients expected in 2H 2023 -- DMT410 partnering discussions ongoing -SAN DIEGO, CA / ACCESSWIRE / February 21, 2023 / Dermata Therapeutics, Inc. (Nasdaq:DRMA; DRMAW) ("Dermata," or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical...

Read more

Lexaria Discovers Potential Novel Mechanism From Hypertension Study HYPER-H21-4

February 21, 2023 9:00 AM

KELOWNA, BC / ACCESSWIRE / February 21, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce additional findings from its human clinical study HYPER-H21-4 ("the Study") demonstrating a potentially novel mechanism of action of its patented DehydraTECH-processed cannabidiol ("CBD") capsule formulation in reducing blood pressure ("BP").The Food...

Read more

EV Biologics Generates Mesenchymal Stem Cell Lines

February 21, 2023 8:00 AM

TAMPA, FL / ACCESSWIRE / February 21, 2023 / EV Biologics Corp (OTC PINK:YECO), today announced that it has successfully generated several mesenchymal stem/stromal cell (MSC) lines for secretome production and further cell line development.The cell banks were isolated from rigorously screened human donor tissue using xeno-free, serum-free culture media for isolation and expansion, after obtaining informed consent (from donors) for research and...

Read more

Invitation to Presentation of BioInvent's Year-End Report 2022

February 21, 2023 4:50 AM

LUND, SWEDEN / ACCESSWIRE / February 21, 2023 / BioInvent International (STO:BINV)BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) invites investors and analysts to a presentation of the Year-end report 2022 at 2:00 pm CET on February 22. The report will be published at 8:00 am CET the same day.BioInvent's CEO Martin Welschof will present the report together with CFO Stefan Ericsson. The presentation will be held in English.When:...

Read more

TISSIUM Selected for the French Tech 120 Program

February 20, 2023 10:30 AM

PARIS, FRANCE / ACCESSWIRE / February 20, 2023 / TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, confirms its selection for the fourth year in a row in the French Tech 120 Program by joining the class of 2023, the most selective class since the creation of the program.Launched in 2019 by the Mission French Tech, the French Tech 120 is a program from the Government to support the...

Read more

Leading Operations Executive Adi Shemer Joins AppYea's Advisory Board

February 16, 2023 9:25 AM

GAN YAVNE, ISRAEL / February 16, 2023 / AppYea Inc. (OTCQB:APYP), a developer of accurate wearable monitoring solutions to treat sleep apnea and snoring, is pleased to announce the addition of Adi Shemer to the advisory board of the Company, effective immediately.Mr. Shemer brings extensive experience in senior operations, management and control of production processes, establishment, and management of logistics systems. Mr. Shemer established...

Read more

NovAccess Global to Present at World Orphan Drug Congress

February 16, 2023 9:00 AM

CLEVELAND, OH / ACCESSWIRE / February 16, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced that its CEO Dr. Dwain Irvin has been invited to present at the World Orphan Drug Congress, scheduled for May 23-25, 2023, near Washington, DC. Dr. Christopher Wheeler, Ph.D., President, StemVax Therapeutics Inc., a division of NovAccess Global and the lead scientist...

Read more

Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Prostate Cancer at ASCO GU Cancers Symposium

February 16, 2023 8:00 AM

Gedatolisib demonstrated superior potency and efficacy in prostate cancer cell lines compared to other PI3K/AKT/mTOR inhibitors evaluated regardless of PI3K or PTEN statusMINNEAPOLIS, MN / ACCESSWIRE / February 16, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today presented data from preclinical studies evaluating gedatolisib and other PI3K/AKT/mTOR...

Read more

Ensysce Biosciences Receives Positive Nasdaq Listing Determination

February 15, 2023 4:10 PM

SAN DIEGO, CA / ACCESSWIRE / February 15, 2023 / Ensysce Biosciences, Inc. (the "Company") (NASDAQ:ENSC), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that by decision dated February 14, 2023, a Nasdaq Hearings Panel (the "Panel") granted the Company's request for continued listing on The Nasdaq Stock Market ("Nasdaq"), subject to the Company...

Read more

Artelo Biosciences to Present at MicroCap Rodeo’s Annual Winter Wonderland – Best Ideas Virtual Investor Conference on February 22, 2023

February 15, 2023 8:30 AM

SOLANA BEACH, CA / ACCESSWIRE / February 15, 2023 / Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that it has been invited to present at MicroCap Rodeo's Third Annual Winter Wonderland - Best Ideas Virtual Investor conference, which is being held virtually on...

Read more

Midatech Pharma PLC Announces Closing of $6.0m Private Placement & Broker Change

February 15, 2023 3:05 AM

ABINGDON, UK / ACCESSWIRE / February 15, 2023 / Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines, announces the closing of the Private Placement of 10,344,822 Units initially at an issue price of US$0.58 per Unit (further details of which were set out in the announcement of 9 February 2023).Each such Unit comprises either (i) one American...

Read more

ITOCO Secures 17k-Hectare Land Package

February 14, 2023 7:00 AM

TORONTO, ON / ACCESSWIRE / February 14, 2023 / ITOCO INC. (OTC PINK:ITMC) is pleased to announce the completion of the first stage with International ASEAN Corporation (IAC) and Treasury Core Corp. to develop agricultural land rehabilitation initiatives in land holdings of Ingonyama Trust, Pietermaritzburg, South Africa.The Ingonyama Trust has confirmed the allocation of 17,000 hectares, with an additional 10,000 soon to be allocated, for...

Read more

Edesa Biotech Reports Fiscal 1st Quarter 2023 Results

February 10, 2023 9:00 AM

TORONTO, ON / ACCESSWIRE / February 10, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three months ended December 31, 2022 and provided an update on its business.During the fiscal first quarter, the U.S. Food and Drug Administration (FDA) granted Fast Track designation for Edesa's drug candidate, EB05, which the...

Read more

Cube Psytech Signs Letter of Intent to Acquire Translational Life Sciences and Announces Private Placement

February 10, 2023 8:00 AM

VANCOUVER, BC / ACCESSWIRE / February 10, 2023 / Cube Psytech Holdings Inc. (the "Company" or "CUBE"), a biopharmaceutical and biotechnology company focused on the research and development of functional and psychedelic mushroom technologies for use in natural healthcare products, is pleased to announce that it has entered into a letter of intent ("LOI") to acquire Translational Life Sciences ("TLS"). TLS will join Cube Psytech Corp. and Cube...

Read more

Midatech Pharma PLC Announces Private Placement Raising US $6.0 million

February 9, 2023 12:10 PM

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN (THE "ANNOUNCEMENT") IS RESTRICTED AND IS NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES OF SECURITIES WOULD BE PROHIBITED BY APPLICABLE LAW.THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION,...

Read more

enVVeno Medical to Present at Cowen's 43rd Annual Health Care Conference

February 8, 2023 9:00 AM

Live video webcast presentation on Wednesday, March 8th at 9:10 AM ETIRVINE, CA / ACCESSWIRE / February 8, 2023 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that Robert Berman, CEO of enVVeno Medical, will present at Cowen's 43rd Annual Health Care Conference on Wednesday, March 8, 2023 at 9:10 AM ET. The conference...

Read more

Enzolytics Announces Preliminary Results of GLP Toxicology Study for its anti-HIV Therapeutic ITV-1 and Production of ITV-1 for Initiation of Registration in Africa

February 8, 2023 6:00 AM

COLLEGE STATION, TX / ACCESSWIRE / February 8, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/).Enzolytics, Inc. announced today the preliminary results of Toxicology studies of the Company's ITV-1 anti-HIV therapeutic confirming that the therapy is non-toxic and demonstrating the safety of administration of this patented proprietary immunotherapy. Establishing this result is essential to permitting under the European Medicines...

Read more

Biovica Receives CLIA Certification

February 8, 2023 2:20 AM

UPPSALA, SWEDEN / ACCESSWIRE / February 8, 2023 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica, active in cancer monitoring, today announces that the company's test laboratory in San Diego, California, has received CLIA certification allowing Biovica to begin commercial sales of DiviTum® TKa on the US market."The CLIA certification is a critical step for the launch of our recently FDA cleared DiviTum® TKa...

Read more

NovAccess Global Leadership to Present at World Brain Mapping Foundation Annual Congress

February 3, 2023 9:00 AM

Dr. Christopher Wheeler, NovAccess Lead Scientist, to Receive Leadership Award for his ContributionsCLEVELAND, OH / ACCESSWIRE / February 3, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced that its CEO Dr. Dwain Irvin and Dr. Christopher Wheeler, Ph.D., President, StemVax Therapeutics Inc., a division of NovAccess Global and the lead scientist for the...

Read more

Ensysce Biosciences, Inc. Announces $3 Million Registered Direct Offering

February 3, 2023 8:00 AM

SAN DIEGO, CA / ACCESSWIRE / February 3, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that it has entered into a definitive agreement for the purchase and sale of 3,571,431 shares of the Company's common stock at a purchase price of $0.84 per share of common stock in a registered...

Read more